ICICI Prudential Life Insurance Company Ltd Q3 FY26: ₹22,834 Cr revenue, ₹387 Cr PAT, EPS ₹2.67 — and still a 60+ P/E party
1) At a Glance
ICICI Prudential Life (ICICIPRULI) is that one “grown-up” stock in the insurance party that shows up wearing a tie, talks about solvency, and still manages to sneak into valuation debates like it’s a meme coin. Current price is ₹681 with a market cap of ₹98,659 Cr, and the stock has delivered +16.1% in 3 months (so yes, it woke up recently). Reported Stock P/E shows 72, but if we annualise the latest quarterly EPS of ₹2.67, the annualised EPS becomes ₹10.68, and the “my-calculator-is-not-drunk” P/E comes to ~63.8. The business runs on scale—Sales (TTM) ₹75,859 Cr, PAT (TTM) ₹1,369 Cr, ROE 10.4%, ROCE 11.9%, and debt ₹2,595 Cr with Debt/Equity 0.19. The latest quarter (Dec 2025) shows a clean PAT of ₹387 Cr and profit growth (qtr) of ~19.2% while “Sales Qtr Var” looks like it drank 5 energy drinks (+403%)—we’ll talk about that madness. So the question is: are we looking at a premium franchise… or a premium price with a premium headache?
2) Introduction
Life insurance companies are basically long-term money gyms. Customers come in with “I want protection + savings + peace of mind,” and insurers say, “Sure, sign here for 20 years, and we’ll make your money do yoga in the markets.” ICICI Prudential Life sits at the intersection of three powerful things: ICICI Bank’s distribution muscle, Prudential’s global insurance DNA, and India’s never-ending need to protect families while simultaneously chasing returns.
But if you’ve ever tried to “understand” an insurer’s financials like you understand a biscuit company’s sales, welcome to the circus. Insurance P&L lines can look volatile because premium recognition, investment swings, and accounting presentation can make revenue behave like an influencer—dramatic, attention-seeking, and occasionally confusing.
Still, the dataset gives us plenty of hard numbers: the company’s Total Premium is ₹21,251 Cr in H1 FY26, APE ₹4,286 Cr, VNB ₹1,049 Cr, New business margin 24.5%, AUM ₹3,21,000 Cr, Total sum assured ₹42,16,000 Cr, Total cost ratio 19.2%, Solvency 213.2%, and claim settlement ratio 99.3%. That’s not a random small finance company selling policies out of a WhatsApp group. That’s a system-level franchise.
Now the real investor question: if the business is stable and scaled, why does the stock still trade at a rich multiple? And what should you watch so you don’t become the exit liquidity of someone’s “insurance rerating thesis”?
3) Business Model – WTF Do They Even Do?
ICICI Prudential Life sells life insurance, pensions, and health insurance products to individuals and groups. It operates across participating, non-participating, and unit-linked businesses. Translation:
Some products are market-linked (ULIPs), where customers indirectly take equity/debt market risk while the insurer earns fees and margins.
Some are traditional savings/protection products, where the insurer manages the pool and promises structured benefits.
Some are annuities and pensions, where the core game is long-term liability management and pricing discipline.
Distribution is a multi-headed hydra: individual agents, corporate agents, banks, brokers, sales force, and the company website. And the big daddy advantage is the promoter ecosystem—ICICI Bank (51% stake) is also a corporate agent, giving access to branch network and customer base. Prudential holds 22%. So yes, the promoters aren’t just on the cap table; they’re also pushing distribution and oversight.
Operationally, the company claims scale: 2.47+ lakh advisors, 50 bank partnerships, access to 24,300+ bank branches, and 1,400+ non-bank partnerships. Product mix by APE in H1 FY26: Linked 48%, Non-linked 26%, Protection 19%, Annuity 5%, Group funds 6%. Distribution mix by APE: Agency 25%, Bancassurance 30%, Group 18%, Direct 14%, Partnership distribution 13%.
Ask yourself: does this look like a one-trick pony? Or more like an insurance octopus with multiple tentacles grabbing premium? And if that’s the case… why are margins still not exploding like a tech company?
4) Financials Overview (Quarterly Results locked)
Result type detection (locked): QUARTERLY RESULTS The latest official heading in the dump is “Quarterly Results – Consolidated Figures in Rs. Crores.” So EPS annualisation will follow: Annualised EPS = Latest quarterly EPS × 4
Quarterly Comparison Table (₹ Cr, except EPS)
Latest quarter is Dec 2025. Same quarter last year is Dec 2024. Previous quarter is Sep 2025.
Metric
Latest Quarter (Dec 2025)
Same Quarter Last Year (Dec 2024)
Previous Quarter (Sep 2025)
YoY %
QoQ %
Revenue (Sales)
22,834
4,536
11,936
+403.3%
+91.3%
EBITDA (Operating Profit)
741
241
-19
+207.5%
NM
PAT (Net Profit)
387
325
296
+19.1%
+30.7%
EPS (₹)
2.67
2.25
2.04
+18.7%
+30.9%
Notes & roast-worthy commentary:
That Revenue YoY of +403% is not a normal “wow growth” moment. It’s a “your base quarter looks like it fell off a cliff” moment. Dec 2024 revenue is ₹4,536 Cr, while quarters around it (Jun 2024 ₹25,396 Cr; Sep 2024 ₹25,158 Cr) look completely different. So the headline growth is spicy, but the story is accounting/recognition/seasonality noise showing up in a single quarter.
Operating profit flipped from -₹19 Cr in Sep 2025 to +₹741 Cr in Dec 2025. That’s not a small improvement; that’s a full personality change.
PAT growth is much more “real world”: +19% YoY, +31% QoQ. EPS follows the same.
Now, quick reader check: do you prefer businesses with steady-looking numbers, or businesses where one quarter randomly cosplays as a crypto candle?
EPS Annualisation + Recalculated P/E
Latest quarterly EPS (Dec 2025): ₹2.67
Annualised EPS: ₹2.67 × 4 = ₹10.68
Recalculated P/E using CMP ₹681: ₹681 / ₹10.68 ≈ 63.8
Screener shows EPS ₹9.47 (TTM) and P/E ~72, which is consistent with ₹681 / ₹9.47 ≈ 71.9. So both are “correct,” depending on which EPS you use. The only incorrect thing would be pretending 70+ P/E is “cheap because insurance.”
5) Valuation Discussion – Fair Value Range only (Educational)
We’ll use three methods: P/E, EV/EBITDA, and a simple DCF-style sanity check (with clearly stated assumptions, because nobody can do a pure DCF without assumptions unless they’re a magician).
A) P/E Method (using annualised EPS from quarterly results)
CMP = ₹681
Annualised EPS = ₹10.68
If the market values it at:
55× EPS → Fair value ≈ 55 × 10.68 = ₹587
65× EPS → Fair value ≈ 65 × 10.68 = ₹694
75× EPS → Fair value ≈ 75 × 10.68 = ₹801
P/E fair value range: ₹587 – ₹801 (Yes, the range is wide. Welcome to high-multiple land.)
B) EV/EBITDA Method (using latest quarter annualised Operating Profit as proxy)
We only have quarterly “Operating Profit” (no depreciation/interest in the quarterly table). We’ll treat Operating Profit as EBITDA proxy for a rough valuation lens.
Current EV/EBITDA ≈ 1,01,141 / 2,964 ≈ 34.1× (Also, Screener shows EV/EBITDA 53.9—because different EBITDA bases and periods can change this massively.)
Now apply an EV/EBITDA range:
28× → EV ≈ 28 × 2,964 = ₹83,0xx Cr
36× → EV ≈ 36 × 2,964 = ₹1,06,7xx Cr
42× → EV ≈ 42 × 2,964 = ₹1,24,4xx Cr
To convert EV to equity value precisely, you’d adjust for net debt; we only have Debt ₹2,595 Cr and no cash number here, so we keep this as an EV-based range and map loosely to price around current market cap (₹98,659 Cr). This lens basically says: the stock is priced like a premium insurer and does not want to be treated like a boring financial.
EV/EBITDA implied band suggests “around current pricing,” depending on what you believe is sustainable EBITDA.
C) DCF-style sanity check using Cash Flows (last 3 years)
Cash flows (₹ Cr):
Mar 2023: CFO 89, CFI -1,145, CFF -112, Net -1,168
Mar 2024: CFO -7,315, CFI 7,420, CFF -88, Net 17
Mar 2025: CFO -9,413, CFI 6,875, CFF 1,422, Net -1,116
A conventional DCF loves stable positive free cash flow. Here, operating cash flows are negative in two of the last three years, which makes a straight “FCF DCF” not very meaningful from this dataset alone. So the honest conclusion from the dump is: a cash-flow DCF is unreliable here unless you deeply model insurance working capital and liability movements (which we are not doing with this limited table).
So instead of pretending, we use this as a warning: valuation comfort should come more from VNB/EV frameworks and franchise strength, not from CFO-based DCF in this snapshot.
Fair Value Range Summary (educational): ₹587 – ₹801 (P/E lens), with EV/EBITDA broadly consistent with premium pricing. Disclaimer: This fair value range is for educational purposes only and is not investment advice.
Now tell me—do you want valuation comfort from math, or from brand + distribution moat? Because this one demands both.
6) What’s Cooking – News, Triggers, Drama
The announcements section is doing full “corporate adulting” mode:
Jan 13, 2026: Company approved unaudited quarterly and nine-month results ended Dec 31, 2025, plus updated KMP disclosures, and confirmed NCD proceeds used as intended.
Jan 13, 2026: Earnings call audio recording posted for 9M-FY2026.
Jan 12, 2026: Executed SPA to sell 100% of ICICI Prudential Pension Funds (ICICI PFM) to ICICI Bank for ₹2.035 billion.
Jan 5, 2026: PFRDA approval for the same sale (subject to conditions).
There’s a parade of GST orders/demands across FY2018/FY2019/FY2022 with various tax/interest/penalty totals, and the company states it will appeal in multiple cases.
Nov 28, 2025: Allotted 1,19,500 subordinated debentures worth ₹11.95 bn, 10-year tenor, 7.69% coupon, callable after five years.
Credit ratings: ICRA AAA (Stable) reaffirmation with solvency reference; CRISIL AAA/Stable assigned to NCDs.
Also from key points:
Bima Sugam stake: invested ₹10 Cr for 10% stake in Nov 2024.
KMP changes: Deepak Kinger resigns effective Dec 7, 2025; Anand Desai redesignated Chief Risk Officer effective Dec 8, 2025; Manish Bhandari appointed Chief Compliance Officer from Dec 8, 2025.
GST council change: Individual life insurance policies approved to be exempt from GST w.e.f. Sep 22, 2025, and company expects ~1% impact on Embedded Value (value accretive expectation).
So the “drama” is not scandal drama; it’s compliance + capital management + tax litigation drama. The boring kind… which is exactly what you want in financials (unless you’re a Twitter trader).
7) Balance Sheet (Consolidated, ₹ Cr)
Latest available consolidated column is Sep 2025. Using Mar 2024, Mar 2025, Sep 2025:
(₹ Cr)
Mar 2024
Mar 2025
Sep 2025
Total Assets
299,001
314,239
324,512
Net Worth (Equity + Reserves)
11,005
11,933
12,715
Borrowings
1,200
2,600
2,600
Other Liabilities
286,796
299,705
309,197
Total Liabilities
299,001
314,239
324,512
Three quick (and slightly savage) observations:
Net worth is growing, but the balance sheet is basically Other Liabilities doing bodybuilding—because insurance liabilities and reserves are the main game.
Borrowings jumped from ₹1,200 Cr to ₹2,600 Cr and then stayed flat—so leverage isn’t exploding, but it’s not asleep either.
Total assets at ₹3.24 lakh Cr is the real “scale flex.” This is not a small insurer; it’s a capital allocation machine with a policy wrapper.
8) Cash Flow – Sab Number Game Hai (₹ Cr)
(₹ Cr)
Mar 2023
Mar 2024
Mar 2025
Operating Cash Flow
89
-7,315
-9,413
Investing Cash Flow
-1,145
7,420
6,875
Financing Cash Flow
-112
-88
1,422
Cash flows here scream one thing: don’t read insurer CFO like you read an FMCG CFO. Negative operating cash flow in insurers can reflect movements in policy liabilities, fund flows, and timing differences. But as an investor, you still should ask: why is operating cash flow negative two years in a row while PAT is positive? That question
